2015 BioProcess International European Summit

Event date 14 April 2015 – 16 April 2015

Location Swissotel Dusseldorf Hotel, Dusseldorf, Germany

BPI is Informa’s largest European biopharm event. With the upward trend showing an increasing need for the production of biopharmaceuticals at a consistently higher quality and volumes, the importance of developing an effective and efficient bioprocess have never been more significant. The BioProcess International Europe Summit is closely regarded as Europe’s key conference for addressing issues, breakthroughs and developments covering the whole development cycle for the bioprocessing industry. Topics covered include biosimilars, biobetters, manufacturing strategies, QbD, cell culture and upstream processing, recovery and purification, formulation and analytical strategies. • No of Attendee’s: 400+ • No of Participating Companies: 176 • Conference Rating: 4.2 out of 5 • Networking Rating: 4.5 out of 5

Contacts

Daniel Barry

Press contact Dr BPI Europe Project Manager

GE's VP of BioProcess, Nigel Darby talks exclusively to the BPI European Summit

With BioProcessing International Europe less than a month away, we sat down with Nigel Darby, VP of BioProcess GE Healthcare Life Sciences, to discuss the current challenges facing the bioprocessing industry and how the biomanufacturing has changed over the past few years.
More mature industry
“I think if you look at the biomanufacturing industry today, you see a transition to a much more c

22 July 2014 12:19

Is Continuous Processing the next logical step?

Although continuous processing / continuous manufacturing is not a new concept, application in the biopharmaceutical industry is currently not widely accepted. However with advances in technology and emergence of new product types and markets companies are becoming more willing to embrace this.

11 March 2014 14:17

Novasep's Alain Lamproye shares his thoughts on the challenges facing the biotech industry

BPI Europe - In your opinion, what are the top three challenges facing biotech/ bioprocessing at the moment?
AL - Amongst the top challenges seen today in biotech, manufacturing cost control is likely to
be one of the most important, as it is directly related to producers’ profit margin and the
prices of medicinal drugs.. The challenge is even more obvious with the increasing share
of

15 October 2013 14:23

JSR Expands Bioprocess Offerings Through Strategic Investment and Commercial Partnership with Natrix Separations

September 10, 2013 – Tokyo, Japan – JSR Corporation (President: Mitsunobu Koshiba) announced today that it has expanded its Life Sciences initiative with a strategic investment in Natrix Separations,
the developer of Natrix™ HD Membrane Technology and Advective™ Chromatography. The companies have also entered into a global distribution agreement for commercialization of Natrix bioprocess produ

8 April 2013 10:07

Astellas and Ambrx Initiate Antibody Drug Conjugate Collaboration - Meet the two at next week's BioProcess International Europe Conference - 17-18 April 2013

Astellas and Ambrx Initiate Collaboration for Discovery and Development of Next-Generation Antibody Drug Conjugates for Oncology

14 March 2013 08:00

GE Healthcare Life Sciences - Bridging the Gap Between Upstream and Downstream Bioprocessing

BPI Europe's Exclusive interview with Eva Lindskog, GE Healthcare Life Sciences’ Upstream Marketing Segment Leader

27 March 2013 08:00

Conquering the complexities of biologics to get to biosimilars - Fierce Biotech

Biosimilar Manufacturing - Hot Topic for BioProcess International Europe, 17-18 April 2013, Dusseldorf. 15% discount if you mention this article

14 February 2013 15:28

Evolving strategies for successfully developing biosimilars and non-platformed therapeutics

Next-generation therapies such as bi-specifics, fusion proteins and fragments offer tremendous benefits on paper, but it’s the bioprocessing departments that have to develop the new production methods, switch to new platforms and investigate new capture steps.

11 February 2013 15:44

Cell Culture Becomes an Integral Part of Cell Line Development and Engineering

Market demands to reduce manufacturing costs require better Cell culture processes

5 February 2013 08:09

Deal making in the biosimilars market: increasing investment for decreasing return? - DataMonitor

Biosimilars are big business. The global biologics market reached $125 billion in 2011, and is predicted to top $150 billion by the end of 2016. Of this, roughly $60 billion will be in off-patent sales.

31 January 2013 08:00

ADC manufacturing made rapid progress over last five years, says Seattle Genetics

Exclusive Interview with Nathan Ihle, Executive Director, Process Chemistry & Analytical Biochemistry, Seattle Genetics, USA

29 January 2013 13:35

Peter Greenleaf steps down as MedImmune president, Bahija Jallal chosen as replacement

Peter Greenleaf is stepping down down as president of Gaithersburg-based biotechnology giant MedImmune, according to a company spokesman, to take the helm of parent company AstraZeneca’s Latin America business.
He will be replaced by Bahija Jallal, who currently serves as MedImmune’s executive vice president of research and development. Jallal joined the company in 2006 as vice president of tra

3 October 2012 09:00

Europe's Leading Meeting for Bioprocessing Announces Biosimilars, Antibody Drug Conjugates and New Processing Technologies as Key Themes for 2013

The pursuit of Biosimilars, Antibody-Drug Conjugates and New Processing Technologies will set the trend for biomanufacturing in 2013; so says research from the industry's leading conference and exhibition, BioProcess International Europe.

23 January 2015 08:33

Roche Discuss Impact of FDA Breakthrough Designation Therapy on Technical and BioProcessing Departments

The FDA’s Breakthrough Therapy Designation is big news. As of December 29, 2014, the US Agency has given 16 approvals to drugs designated as Breakthrough Therapies, 11 of them first time approvals for novel drugs. For production and analytical teams the question is: “How does this impact us?”

6 February 2015 11:21

Press Invitation and Media Alert for Events Listings: 11th Annual BioProcess International European Summit:

Tuesday 14 - Wednesday 15 April 2015, Swissotel Dusseldorf Neuss, Germany.